Gilder Gagnon Howe & CO LLC Bluebird Bio, Inc. Transaction History

Gilder Gagnon Howe & CO LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$16.59 - $33.89 $4,164 - $8,506	-251 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$27.5 - $37.92 $12.1 Million - $16.7 Million	-441,387 Reduced 99.94%	251 $11,000
Q3 2020 Nov 16, 2020	SELL	$34.44 - $43.75 $5.88 Million - $7.47 Million	-170,826 Reduced 27.89%	441,638 $23.8 Million
Q2 2020 Aug 14, 2020	BUY	$27.12 - $45.97 $1.6 Million - $2.72 Million	59,103 Added 10.68%	612,464 $37.4 Million
Q1 2020 May 15, 2020	BUY	$26.16 - $63.5 $1.13 Million - $2.75 Million	43,248 Added 8.48%	553,361 $25.4 Million
Q4 2019 Feb 14, 2020	BUY	$46.96 - $61.67 $22.5 Million - $29.5 Million	478,352 Added 1506.1%	510,113 $44.8 Million
Q3 2019 Nov 14, 2019	SELL	$59.47 - $93.1 $460,238 - $720,500	-7,739 Reduced 19.59%	31,761 $2.92 Million
Q2 2019 Aug 13, 2019	BUY	$75.84 - $105.21 $43,304 - $60,074	571 Added 1.47%	39,500 $5.02 Million
Q1 2019 May 17, 2019	BUY	$64.44 - $104.11 $1.51 Million - $2.45 Million	23,486 Added 152.08%	38,929 $6.13 Million
Q4 2018 Feb 14, 2019	SELL	$59.1 - $93.26 $12 Million - $18.9 Million	-203,068 Reduced 92.93%	15,443 $1.53 Million
Q3 2018 Oct 30, 2018	BUY	$88.86 - $117.49 $7.12 Million - $9.42 Million	80,145 Added 57.92%	218,511 $31.9 Million
Q2 2018 Jul 31, 2018	SELL	$99.64 - $127.59 $1.45 Million - $1.85 Million	-14,527 Reduced 9.5%	138,366 $21.7 Million
Q1 2018 Apr 30, 2018	BUY	$105.8 - $150.94 $15.4 Million - $22 Million	146,013 Added 2122.28%	152,893 $26.1 Million
Q4 2017 Jan 31, 2018	BUY	$81.25 - $130.7 $559,000 - $899,215	6,880	6,880 $1.23 Million

27M

191K

299K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $561M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.